Hydrogenology
Hydrogenology editorial study record

Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats

Nie C, Zou R, Pan S, A R, Gao Y, Yang H, Bai J, Xi S, Wang X, Hong X, Yang W. · Journal of Cellular and Molecular Medicine. 2021;25(18):8997–9010.

PreclinicalInhaled H₂Published 2021
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Randomized five-group rat myocardial-infarction experiment plus cardiomyocyte and cardiac-fibroblast experiments

Research topic

Cardiovascular and circulatory health

Administration classification

Inhaled H₂

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Male Sprague-Dawley rats with permanent coronary ligation and neonatal-rat cardiomyocytes/cardiac fibroblasts.

Sample

75 rats randomized, n=15 in each of sham, infarction, infarction plus H₂, infarction plus MCC950 and combined-treatment groups; most tissue assays used five surviving rats per group.

Duration

Three hours/day for 28 days after coronary ligation; cell-treatment schedules varied by assay.

Intervention

2% H₂ in air inhaled in a monitored cage for three hours daily for 28 days, alone or with one 30 mg/kg intraperitoneal dose of the NLRP3 inhibitor MCC950.

Hydrogen form

H₂ alone diluted with air — not Brown's gas or oxyhydrogen.

H₂ specification

Air-pump flow and generator H₂ flow were mixed at a reported 50:1 ratio to target 2% H₂, with real-time chamber concentration monitoring; absolute total flow was not reported.

H₂ flow

Not reported in mL/min — only the 50:1 air:H₂ flow ratio was given, so an absolute H₂ flow cannot be calculated.

O₂ delivered with H₂

No supplemental O₂; room air was the carrier, but its absolute flow and resulting O₂ mL/min were not reported.

Comparator

Sham, myocardial infarction alone, MCC950 alone and H₂ plus MCC950 groups; matched cell controls used hypoxia or angiotensin II.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Survival, cardiac function, BNP, oxidative markers, myocardial fibrosis/remodelling, NLRP3-pyroptosis markers and cell viability/fibroblast activation.

Reported result

Cardiac-function, fibrosis, oxidative and inflammasome-related measures generally favored H₂ versus infarction alone. Survival was 8/15 with infarction and 11/15 with H₂, reported descriptively without establishing a definitive survival effect; multiple assays used only five survivors per group.

Results-extraction completeness

The complete free PMC article, figures, supplement-linked methods and disclosures were checked for allocation, mortality, mixture/flow limitations, positive and comparative results, funding and conflicts.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Preclinical model, substantial post-infarction mortality, many analyses restricted to five survivors per group, no absolute gas flow and several mechanistic comparisons. Four Chinese public/institutional grants funded the study; authors reported no conflict of interest and named the commercial H₂ generator.

Applies directly to

Chronic cardiac remodelling after permanent infarction in rats; it does not establish treatment benefit, flow or safety in people.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 34402164 · DOI: 10.1111/jcmm.16863

Publisher access

Free full article in PubMed Central.

Extraction basis

Complete PMC article and PubMed metadata; full-text extraction checked 9 August 2026.

Record revision

2026-08-10